

¹⁰
53. The method of claim ⁸53 wherein each of said first and second polypeptides is 111 amino acid residues in length.

¹¹
56. The method of claim ¹⁰55 wherein each of said first and second polypeptides is glycosylated.

¹²
57. The method of claim ³53 wherein each of said first and second polypeptides comprises residues 226-345 of SEQ ID NO:2.

¹³
58. The method of claim ¹²57 wherein each of said first and second polypeptides is glycosylated.

¹⁴
59. The method of claim ⁸53 wherein said wound is a dermal wound.

¹⁵
60. The method of claim ⁸53 wherein the composition is formulated for topical delivery.--


REMARKS

Claims 46-60 are now in this application. The new claims are fully supported by the specification as filed; no new matter has been added.

The specification has been amended to recite related application data.

Applicants believe all claims now in this application are in condition for allowance, and early notice to that effect is requested. If for any reason the Examiner feels that a telephone conference would expedite prosecution of the application, the Examiner is invited to telephone the undersigned at (206) 442-6673.

Respectfully Submitted,



Gary E. Parker
Registration No. 31,648

ZymoGenetics, Inc.
1201 Eastlake Avenue East
Seattle, WA 98102
Tel. 206-442-6673
Fax 206-442-6678

09706968
110600

L

175

A